Therapeutic Response

HER2-negative status confers therapeutic sensitivity to Bevacizumab in combination with Paclitaxel in patients with Invasive Breast Carcinoma.

Statements

Source and description
Bevacizumab 10mg/kg - 14 days. NCCP National SACT Regimen. HSE. The Republic of Ireland's Health Service Executive (HSE) has approved bevacizumab in combination with paclitaxel for reimbursement as a treatment option for the treatment of patients with HER2-negative metastatic breast cancer.
Bevacizumab 15mg/kg Therapy - 21 days. NCCP National SACT Regimen. HSE. The Republic of Ireland's Health Service Executive (HSE) has approved bevacizumab in combination with paclitaxel for reimbursement as a treatment option for the first-line treatment of patients with HER2-negative metastatic breast cancer.